MedPath

ADX-324

Generic Name
ADX-324

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Jun 4, 2025

ADX-324: An Investigational siRNA Therapeutic for Hereditary Angioedema

I. Executive Summary

ADX-324 is an investigational short-interfering RNA (siRNA) therapeutic agent under development by ADARx Pharmaceuticals, Inc., primarily for the prophylactic treatment of Hereditary Angioedema (HAE).[1] The therapeutic strategy of ADX-324 centers on the specific targeting and reduction of plasma prekallikrein (PKK) production, a pivotal protein in the pathophysiological cascade leading to bradykinin generation and subsequent angioedema attacks characteristic of HAE. This is achieved through the RNA interference (RNAi) mechanism, where ADX-324 is designed to silence the KLKB1 messenger RNA (mRNA).[2]

A key feature of ADX-324's development is its utilization of ADARx Pharmaceuticals' proprietary RNA targeting platform. This platform incorporates technologies for liver-directed delivery, primarily through N-acetylgalactosamine (GalNAc) conjugation (referred to as PLR™ - Preeminent Liver RNA, or CTD™ - Cell-Targeted Delivery technology), and advanced oligonucleotide optimization strategies (known as SPE™ - Sequence Specific Platform Enhancement, or MST™ - mRNA Silencing Technology) to enhance potency, stability, and duration of action.[1]

Preclinical investigations, notably studies conducted in non-human primates, have provided encouraging data supporting the potential for ADX-324 to be administered via a long-acting, low-volume subcutaneous dosing regimen, possibly on a bi-annual or even annual basis.[1] Such a dosing schedule would represent a significant advancement in convenience and treatment burden reduction for HAE patients. Pharmacodynamic data from these preclinical efforts were presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in November 2023, signaling progress in understanding the drug's activity profile.[8]

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.